Working… Menu

Topical Bromfenac for Intraoperative Miosis and Pain Reduction

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03831984
Recruitment Status : Enrolling by invitation
First Posted : February 6, 2019
Last Update Posted : February 6, 2019
Information provided by (Responsible Party):
Maria Camila Aguilar Sierra, Hospital de La Luz

Brief Summary:
To evaluate the effect of bromfenac ophthalmic solution 0.09% for reduction of intraoperative miosis and pain in patient who have undergone femtosecond laser-assisted cataract surgery.

Condition or disease Intervention/treatment Phase
Cataract Drug: 0,09% Bromfenac Drug: 0,1% sodium hyaluronate Phase 4

Detailed Description:
This prospective cross-sectional randomized clinical study included 60 patients with senile cataract in the absence of significant ocular comorbidity. The patients received 0.09% bromfenac ophthalmic solution or control placebo twice a day for 3 days before surgery. Pupil diameter was measured at the initiation and finalization of femtosecond laser-assisted cataract surgery and pain quantification was assessed by analogous pain scale at one day follow-up.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Investigator)
Primary Purpose: Treatment
Official Title: Topical 0,09% Bromfenac for Intraoperative Miosis and Pain Reduction in Femtosecond Laser-assisted Cataract Surgery
Actual Study Start Date : March 1, 2018
Actual Primary Completion Date : November 30, 2018
Estimated Study Completion Date : March 30, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cataract

Arm Intervention/treatment
Active Comparator: 0,09% Bromfenac
Topical 0,09% Bromfenac twice daily 3 days before surgery
Drug: 0,09% Bromfenac
topical 0,09% Bromfenac, one drop twice daily 3 days before surgery
Other Name: Zebesten

Placebo Comparator: 0,1% sodium hyaluronate
Topical 0,1% sodium hyaluronate twice daily 3 days before surgery
Drug: 0,1% sodium hyaluronate
topical 0,1% sodium hyaluronate, one drop twice daily 3 days before surgery
Other Name: Hyabak

Primary Outcome Measures :
  1. intraoperative miosis [ Time Frame: 2 days ]
    Evaluation of reduction of intraoperative miosis before and after femtosecond laser assisted cataract surgery

Secondary Outcome Measures :
  1. postoperative pain [ Time Frame: 1 day ]
    Evaluation of reduction of postoperative pain using a visual analogue scale

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Male and female
  • Subjects 18 years or older
  • Patients scheduled for unilateral femtosecond laser-assisted cataract surgery cataract surgery with posterior chamber (PC) IOL implantation.

Exclusion Criteria:

  • Presence of corneal abnormalities
  • History of intraocular surgery
  • History of ocular or systematic diseases (glaucoma, diabetes, uveitis
  • Regular, systemic use of steroid or NSAIDs during the previous 3 months

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03831984

Layout table for location information
Maria Camila Aguilar Sierra
Ciudad de Mexico, Mexico, 06030
Sponsors and Collaborators
Hospital de La Luz
Layout table for investigator information

Layout table for additonal information
Responsible Party: Maria Camila Aguilar Sierra, MD, Hospital de La Luz Identifier: NCT03831984     History of Changes
Other Study ID Numbers: MAguilarSierra
First Posted: February 6, 2019    Key Record Dates
Last Update Posted: February 6, 2019
Last Verified: February 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Maria Camila Aguilar Sierra, Hospital de La Luz:
femtosecond laser
Additional relevant MeSH terms:
Layout table for MeSH terms
Lens Diseases
Eye Diseases
Hyaluronic Acid
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs
Protective Agents
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Anti-Inflammatory Agents
Antirheumatic Agents